22 June 2017 EMA/PRAC/337624/2017 Pharmacovigilance Risk Assessment Committee (PRAC)
New product information wording – Extracts from PRAC recommendations on signals Adopted at the 6-9 June 2017 PRAC
The product information wording in this document is extracted from the document entitled ‘PRAC recommendations on signals’ which contains the whole text of the PRAC recommendations for product information update, as well as some general guidance on the handling of signals. It can be found here (in English only). New text to be added to the product information is underlined. Current text to be deleted is struck through.
1. Gabapentin – Respiratory depression without concomitant opioid use (EPITT no 18814) Summary of product characteristics 4.4. Special warnings and precautions for use Concomitant use with opioids […] Respiratory depression Gabapentin has been associated with severe respiratory depression. Patients with compromised respiratory function, respiratory or neurological disease, renal impairment, concomitant use of CNS depressants and the elderly might be at higher risk of experiencing this severe adverse reaction. Dose adjustments might be necessary in these patients.
4.8. Undesirable effects Respiratory, thoracic and mediastinal disorders Frequency ‘rare’: Respiratory depression
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5525 Send a question via our website www.ema.europa.eu/contact
Package leaflet 2. What you need to know before you take Warnings and precautions Talk to your doctor or pharmacist before taking […] - if you have nervous system disorders, respiratory disorders, or you are more than 65 years old, your doctor may prescribe you a different dosing regimen
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. In particular, tell your doctor (or pharmacist) if you are taking or have been recently taking any medicines for convulsions, sleeping disorders, depression, anxiety, or any other neurological or psychiatric problems.
4. Possible side effects Contact your doctor immediately if you experience any of the following symptoms after taking this medicine as they can be serious: […] - breathing problems, which if severe you may need emergency and intensive care to continue breathing normally
Rare (may affect up to 1 in 1,000 people): […] - Trouble breathing, shallow breaths (respiratory depression)
New product information wording – Extracts from PRAC recommendations on signals EMA/PRAC/337624/2017
Jul 20, 2017 - New product information wording â Extracts from PRAC .... in the fertile age and patients with reduced cerebral compliance (e.g. meningitis,.
Apr 21, 2017 - It can be found here. (in English only). New text to be added to the product information is underlined. Current text to be deleted is struck through ...
May 26, 2016 - Send a question via our website www.ema.europa.eu/contact ... calciphylaxis that can start with a painful skin rash but can lead to other serious ...
Jun 23, 2016 - The product information wording in this document is extracted from the document entitled 'PRAC recommendations on signals' which contains ...
Dec 14, 2017 - The product information wording in this document is extracted from the document entitled 'PRAC recommendations on signals' which contains the whole text of the PRAC recommendations for product information update, as well as some genera
Oct 13, 2016 - Send a question via our website www.ema.europa.eu/contact ... Always take this medicine exactly as your doctor or pharmacist has told you. .... Tell your doctor immediately and stop taking metronidazole if you develop:.
Sep 15, 2016 - Send a question via our website www.ema.europa.eu/contact ... As liver function may change during treatment with {product name}, a close monitoring of ... may need to increase the frequency of your blood tests to check how ...
Jul 21, 2016 - Send a question via our website www.ema.europa.eu/contact ... frequency of these reactions is considered not known (cannot be estimated from the available data) ... 2 - What you need to know before you take [Product name].
Jan 26, 2017 - Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5525 ... New product information wording â Extracts from PRAC ... System Organ.
Jan 25, 2018 - 30 Churchill Place â Canary Wharf â London E14 5EU â United Kingdom. An agency of the European ... The product information wording in this document is extracted from the document entitled 'PRAC ... information update, as well as
Signature. The DIA Europe, Middle East & Africa Contact Centre Team will be ... captured during the conference through video, photo, and/or digital camera, ...
Aug 2, 2017 - ... EudraVigilance system to the new one, a 10 business day downtime is re- quired ... tions have now been added for initial testing of software/system .... qualified persons for pharmacovigilance (QPPVs) and companies' man-.
Sep 19, 2017 - Signature ... By attending the event, you give permission for images of you, captured during the conference through video, photo, and/or digital ...
Apr 10, 2017 - lifecycle. 2. Pharmacovigilance processes. 3. EU Network projects on .... 2016, it was clear that, while the service was improving, there was still ...
Apr 28, 2017 - 2. The United Kingdom will then become a 'third country'. 3. Preparing for the withdrawal is therefore not just a matter for EU and national authorities, but also for private parties. In view of the considerable uncertainties, in parti
May 30, 2017 - Pharmaceutical companies are invited to present their pre-clinical data pertaining to ... patients per year, as many questions about the best use of ALK ... of knowledge and evidence to support the planning and regulatory.
Mar 8, 2018 - Treatment of uterine fibroids. Haematology. New medicines authorised. ⢠Adynovi (rurioctocog alfa pegol). Treatment and prevention of bleeding in patients with haemophilia A. New information on authorised medicines. ⢠Feraccru (ferr
Jan 26, 2017 - is an antiparasitic medicine that treats the Varroa mite infestation in honey-bee colonies, which is considered to be the most significant parasitic ...
Treatment of cystine crystal deposits in the eye. New information on authorised medicines. Lucentis (ranibizumab) - change in indication. Treatment of visual ...